<code id='64800843C6'></code><style id='64800843C6'></style>
    • <acronym id='64800843C6'></acronym>
      <center id='64800843C6'><center id='64800843C6'><tfoot id='64800843C6'></tfoot></center><abbr id='64800843C6'><dir id='64800843C6'><tfoot id='64800843C6'></tfoot><noframes id='64800843C6'>

    • <optgroup id='64800843C6'><strike id='64800843C6'><sup id='64800843C6'></sup></strike><code id='64800843C6'></code></optgroup>
        1. <b id='64800843C6'><label id='64800843C6'><select id='64800843C6'><dt id='64800843C6'><span id='64800843C6'></span></dt></select></label></b><u id='64800843C6'></u>
          <i id='64800843C6'><strike id='64800843C6'><tt id='64800843C6'><pre id='64800843C6'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:4391
          Suzanne KreiterGlobe staff

          The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

          But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

          advertisement

          Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi
          FDA panel unanimously endorses Eisai’s Alzheimer’s drug Leqembi

          AdobeExpertadviserstotheFoodandDrugAdministrationonFridayvotedunanimouslyinfavorof expandingtheappro

          read more
          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more

          DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

          2:23FloridaGovernorRonDeSantisattendsabarbecueinRye,NewHampshire,July30,2023.RebaSaldanha/ReutersRiv